Cefotaxime Sodium API Market

Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.

Cefotaxime Sodium API Market contains market size and forecasts of Cefotaxime Sodium API in global, including the following market information:

Global Cefotaxime Sodium API Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Cefotaxime Sodium API Market Sales, 2017-2022, 2023-2028, (MT)

Global top five Cefotaxime Sodium API companies in 2021 (%)

The global Cefotaxime Sodium API market was valued at 104.1 million in 2021 and is projected to reach US$ 98.7 million by 2028, at a CAGR of -0.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

ChP Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cefotaxime Sodium API include REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, NCPC, Aurobindo Pharma, United Laboratories and Orchid Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Cefotaxime Sodium API manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cefotaxime Sodium API Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Cefotaxime Sodium API Market Segment Percentages, by Type, 2021 (%)

ChP

USP

EP

Global Cefotaxime Sodium API Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Cefotaxime Sodium API Market Segment Percentages, by Application, 2021 (%)

Single Injection

Compound Injection

Global Cefotaxime Sodium API Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Cefotaxime Sodium API Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cefotaxime Sodium API revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Cefotaxime Sodium API revenues share in global market, 2021 (%)

Key companies Cefotaxime Sodium API sales in global market, 2017-2022 (Estimated), (MT)

Key companies Cefotaxime Sodium API sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

REYOUNG

Nectar Lifesciences

Medya Pharma

Sandoz

Kelun

NCPC

Aurobindo Pharma

United Laboratories

Orchid Pharma

CSPC

Kopran

Covalent

ACS Dobfar

Dawnrays

Sterile India